Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
The Arturo Santos portfolio currently includes 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner, which indicates a centralized prosecution process for the entity's current intellectual property. The application is assigned to 1 distinct art unit, reflecting a specific technical focus for the pending innovation within the biotechnology field.
FAY, ZOHREH ALEMZADEH is the busiest examiner for the portfolio, overseeing 1 busiest examiner pending office action. This individual is responsible for the 1 busiest examiner pending office action currently active. Consequently, the immediate prosecution success for Arturo Santos is entirely dependent on the decisions and timelines of this 1 distinct examiner within the 1 distinct art unit.
For a patent practitioner, this concentration means that the prosecution strategy should be highly tailored to the specific tendencies of FAY, ZOHREH ALEMZADEH. Since there is only 1 distinct art unit involved, there is no opportunity to compare examination styles across different units for this portfolio. The singular nature of the matters in the Biotechnology & Pharmaceuticals technology area simplifies the management of the portfolio but increases the impact of a single examiner's perspective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FAY, ZOHREH ALEMZADEH | 1 | 52.2% | -6.2% |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18010099 | TRIAMCINOLONE ACETONIDE-LOADED LIPOSOMES TOPICAL OPHTHALMIC FORMULATIONS AS PRIMARY THERAPY FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION | FAY, ZOHREH ALEMZADEH | 1617 | §103DP | Final Rejection | — | Pending | Dec 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial